Recommended Global Infectious Diseases Webinars & Conferences

Europe & UK

Tuberculosis 2026, France Rare Diseases Congress 2026, Czech Republic INFECTIOUS DISEASES-2026, France Infection Congress 2026, UK Euro Infectious Diseases 2026, UK

Asia Pacific & Middle East

Canada

Euro Infectious Diseases 2026

About Conference

The 18^th Euro-Global Conference on Infectious Diseases will take place on April 16–17, 2026 in the vibrant city of London, United Kingdom. This prestigious event brings together leading minds from across the globe to explore the most pressing challenges and breakthroughs in the field of infectious diseases.

This year’s conference will provide a global platform for researchers, clinicians, microbiologists, epidemiologists, public health experts, pharmaceutical professionals, and industry leaders to share their latest findings and collaborate on strategies to combat infectious threats. Attendees can expect a dynamic and interactive program featuring plenary sessions, keynote speeches, oral and poster presentations, panel discussions, and industry-led workshops.

Key focus areas include:

Emerging and re-emerging infectious diseases
Antimicrobial resistance and new therapeutic strategies
Vaccine development and immunization programs
Infection control, diagnostics, and clinical microbiology
Public health policies and pandemic preparedness

The conference encourages active participation through abstract submissions, offering opportunities for professionals and early-career researchers to present their work and receive international recognition. All accepted abstracts will be published with DOI in reputed journals.

Join us in London to engage with experts, explore innovative technologies, and forge partnerships that shape the future of global health.

Be part of the dialogue. Be part of the solution.

Session & Tracks

1. Bacterial Infections and Antimicrobial Resistance (AMR)

Bacterial infections are caused by pathogenic bacteria and range from mild illnesses to life-threatening conditions like sepsis, pneumonia, and meningitis. While antibiotics have been instrumental in treating these infections, the widespread misuse and overuse of these drugs have led to antimicrobial resistance (AMR). AMR occurs when bacteria evolve mechanisms to resist the effects of antibiotics, rendering standard treatments ineffective. This global health threat is increasing in both community and healthcare settings. Resistant bacteria such as MRSA and drug-resistant Klebsiella complicate treatment, increase hospital stays, and raise mortality rates. Addressing AMR requires surveillance, stewardship, and the development of new antibiotics and alternative therapies. Prevention also involves infection control, vaccination, and public education. Understanding resistance mechanisms and investing in research and diagnostics are critical to combatting this crisis and preserving the effectiveness of current and future antibacterial treatments.

Related Societies: World Health Organization (WHO) | European Centre for Disease Prevention and Control (ECDC) | Centres for Disease Control and Prevention (CDC) | International Society for Infectious Diseases (ISID) | Global Outbreak Alert and Response Network (GOARN) | Public Health England (PHE)

2. Fungal Infections: Diagnosis and Emerging Threats

Fungal infections are caused by a variety of organisms, including yeasts like Candida, molds such as Aspergillus, and dimorphic fungi. These infections range from superficial conditions affecting the skin and mucous membranes to invasive systemic infections that pose serious health risks, particularly for immunocompromised individuals. The growing emergence of drug-resistant fungal strains, such as Candida auris, has become a major concern in healthcare settings. Diagnosis remains challenging due to limited rapid diagnostic tools and often nonspecific symptoms, leading to delayed treatment and higher mortality rates. Environmental changes, increased use of immunosuppressive therapies, and hospital-acquired infections have contributed to the rising incidence of fungal diseases. Addressing this threat requires improved diagnostic techniques, development of novel antifungal agents, and enhanced awareness among clinicians and healthcare providers. Surveillance and timely treatment are key to reducing the burden of fungal infections globally.

3. Viral Infections: Trends, Variants, and Global Impact

Viral infections are caused by microscopic agents that rely on host cells for replication. They can lead to a wide range of illnesses, from the common cold to severe diseases like HIV, Ebola, and influenza. Viruses are highly adaptive and capable of frequent mutations, resulting in the emergence of new variants with increased transmissibility or resistance to treatments. This genetic variability complicates vaccine development and disease control. Global health threats such as COVID-19 have demonstrated how rapidly viral infections can spread and overwhelm healthcare systems. Some viruses, like hepatitis or HPV, can cause chronic infections or even cancer. Preventive measures such as vaccination, antiviral medications, hygiene, and public health campaigns are vital in managing viral outbreaks. Continued research is needed to improve diagnostics, monitor mutations, and develop broad-spectrum antivirals and next-generation vaccines to protect against both endemic and emerging viral diseases.

4. Tuberculosis and Mycobacterial Diseases

Tuberculosis (TB), caused by Mycobacterium tuberculosis, remains one of the deadliest infectious diseases globally. It primarily affects the lungs but can also involve other organs such as the spine, kidneys, and brain. TB spreads through airborne particles and thrives in overcrowded or resource-limited settings. Despite the availability of effective antibiotics, TB control is hampered by drug resistance, with multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains posing significant treatment challenges. In addition to TB, nontuberculous mycobacteria (NTM) are emerging as important pathogens, especially in individuals with underlying lung conditions or weakened immunity. Diagnosis of mycobacterial infections can be complex and often delayed due to slow-growing organisms and non-specific symptoms. Enhancing diagnostic tools, promoting treatment adherence, and strengthening public health strategies are essential for managing TB and related diseases. Vaccination, early detection, and improved access to care remain critical in reducing transmission and mortality.

5. HIV/AIDS and Sexually Transmitted Infections (STIs)

HIV (Human Immunodeficiency Virus) attacks the body’s immune system and, if untreated, can progress to AIDS (Acquired Immunodeficiency Syndrome). HIV is primarily transmitted through unprotected sex, blood exposure, or from mother to child during childbirth. Antiretroviral therapy (ART) allows people with HIV to live longer, healthier lives, but access and adherence remain global challenges. Alongside HIV, sexually transmitted infections (STIs) such as syphilis, gonorrhoea, chlamydia, and HPV continue to affect millions worldwide. STIs can cause severe reproductive health complications, increase HIV transmission risk, and often remain undiagnosed due to a lack of symptoms. The rise of antimicrobial-resistant STIs adds urgency to control efforts. Prevention strategies include safer sex practices, routine screening, timely treatment, and vaccination programs (e.g., HPV vaccine). Education, stigma reduction, and access to sexual health services are essential for reducing transmission and improving health outcomes.

6. Sepsis and Critical Infections in Clinical Practice

Sepsis is a life-threatening condition that occurs when the body’s response to infection causes widespread inflammation, leading to organ dysfunction or failure. It can result from bacterial, viral, or fungal infections and is a major cause of death in hospitals worldwide. Early symptoms—such as fever, confusion, rapid breathing, or low blood pressure—may be subtle, making timely diagnosis challenging. Delays in recognizing and treating sepsis significantly increase mortality risk. Clinical guidelines emphasize prompt administration of antibiotics, fluid resuscitation, and organ support in intensive care settings. Despite advancements, sepsis remains underdiagnosed, with limited biomarkers for early detection. Multidisciplinary care, robust hospital protocols, and public awareness campaigns are vital to reducing its impact. Ongoing research focuses on precision medicine approaches, rapid diagnostics, and improved clinical decision-making tools to prevent progression and improve survival outcomes in sepsis patients.

7. Zoonotic and Vector-Borne Diseases

Zoonotic diseases are infections that jump from animals to humans, while vector-borne diseases are transmitted via carriers like mosquitoes or ticks. These diseases include rabies, Ebola, bird flu, Lyme disease, malaria, dengue, Zika virus, and more. Factors such as global travel, urbanization, deforestation, and climate change have intensified the emergence and spread of these infections. Many zoonoses originate in wildlife and can evolve rapidly, posing significant pandemic threats. Vector-borne diseases often thrive in tropical and subtropical regions where vector control is inadequate. Effective prevention strategies involve animal surveillance, public education, vaccination (where applicable), and integrated vector management. Research into environmental drivers and host-pathogen interactions is essential to predict outbreaks. The “One Health” approach—linking human, animal, and environmental health—is increasingly recognized as crucial in managing these diseases and preventing future pandemics through coordinated global action.

Related Societies: One Health Commission (OHC) | World Organisation for Animal Health (WOAH) | Eco Health Alliance | Global One Health Initiative (GOHi) | Society for Tropical Medicine and Hygiene (ASTMH) | International Veterinary Vaccinology Network (IVVN)

8. Parasitic Infections and Neglected Tropical Diseases (NTDs)

Parasitic infections affect billions of people worldwide, particularly in low-income, tropical, and subtropical regions. These diseases are caused by protozoa (e.g., malaria, giardiasis), helminths (e.g., schistosomiasis, ascariasis), and ectoparasites (e.g., lice, scabies). Neglected Tropical Diseases (NTDs), a group of 20 conditions identified by the WHO, include several parasitic infections and affect impoverished communities with limited access to clean water, sanitation, and healthcare. These diseases can cause chronic illness, disability, and economic hardship. Despite their prevalence, NTDs receive less research funding and global attention compared to other infectious diseases. Efforts to control and eliminate parasitic diseases include mass drug administration, vector control, improved diagnostics, and community education. Climate change and population movements are contributing to the spread of parasitic infections into new regions. Addressing these challenges requires global collaboration, sustained investment, and integration of disease control into primary health systems.

9. Respiratory Tract Infections: Viral and Bacterial Perspectives

Respiratory tract infections (RTIs) affect the airways and lungs and are among the most common causes of illness worldwide. They are classified into upper (e.g., colds, sinusitis) and lower (e.g., pneumonia, bronchitis) respiratory infections and can be caused by bacteria or viruses. Common pathogens include Streptococcus pneumoniae, Haemophilus influenzae, influenza virus, respiratory syncytial virus (RSV), and coronaviruses. RTIs can range from mild to life-threatening, particularly in the elderly, infants, or immunocompromised individuals. Diagnosis often relies on clinical symptoms, though rapid diagnostic tools and imaging may be needed for severe cases. Antibiotics are effective for bacterial infections but not for viral ones—highlighting the importance of accurate diagnosis and responsible prescribing. Vaccination, hygiene measures, and smoking cessation play crucial roles in prevention. Continued surveillance, research into emerging strains, and public health education are essential to managing the burden of respiratory infections globally.

10. Pediatric Infectious Diseases and Immunization Programs

Children are particularly vulnerable to infectious diseases due to their developing immune systems and frequent exposure in schools or day-care settings. Pediatric infectious diseases include measles, mumps, whooping cough, influenza, RSV, rotavirus, and more. Many of these illnesses can lead to serious complications, especially in infants or children with underlying health conditions. Immunization is one of the most effective tools in reducing child morbidity and mortality from infectious diseases. Routine childhood vaccines protect against a range of bacterial and viral illnesses, contributing to herd immunity and overall public health. Delays or gaps in immunization schedules, vaccine hesitancy, and inequitable access to healthcare services can compromise protection. Pediatric infection specialists also monitor antibiotic use to prevent resistance. Integrated strategies—including caregiver education, timely vaccination, and improved diagnostic capacity—are essential for the early detection, prevention, and effective treatment of infectious diseases in children.

11. Infection Control and Hospital-Acquired Infections (HAIs)

Hospital-acquired infections (HAIs), also known as nosocomial infections, are infections that patients acquire during their stay in healthcare facilities, often unrelated to their initial diagnosis. Common HAIs include bloodstream infections, urinary tract infections, ventilator-associated pneumonia, and surgical site infections. Pathogens such as Staphylococcus aureus (including MRSA), Clostridium difficile, and multidrug-resistant Gram-negative bacteria are frequently involved. These infections can lead to longer hospital stays, increased healthcare costs, and higher mortality. Effective infection control practices—such as hand hygiene, sterilization protocols, antimicrobial stewardship, and isolation procedures—are critical in preventing HAIs. Surveillance systems and infection control teams play a vital role in identifying outbreaks and ensuring compliance. Education of healthcare staff and integration of evidence-based guidelines significantly reduce risks. The ongoing emergence of resistant organisms underscores the need for robust infection prevention programs and continuous innovation in diagnostics and disinfection technologies.

12. Diagnostics and Molecular Tools in Infectious Disease

Accurate and timely diagnosis is fundamental in the management and control of infectious diseases. Traditional methods like culture and microscopy are often time-consuming or limited in sensitivity. Molecular diagnostics—such as polymerase chain reaction (PCR), next-generation sequencing (NGS), and CRISPR-based tools—have revolutionized infectious disease detection. These methods allow for rapid identification of pathogens, genotyping, resistance profiling, and outbreak tracking. Point-of-care diagnostics, especially in low-resource settings, enable earlier treatment decisions and better patient outcomes. Serological assays, antigen tests, and biosensors also complement molecular tools in detecting both active and past infections. Artificial intelligence and machine learning are increasingly being integrated with diagnostic platforms to improve interpretation and prediction. While advances have increased testing speed and accuracy, challenges remain around cost, accessibility, and infrastructure. Ongoing innovation and global collaboration are crucial for expanding the reach and effectiveness of diagnostic tools in infectious disease management.

13. One Health and Emerging Global Threats

The One Health approach recognizes that the health of humans, animals, and ecosystems are interconnected. Many emerging infectious diseases—including Ebola, COVID-19, avian influenza, and Nipah virus—have zoonotic origins, highlighting the need for integrated surveillance and response systems. Environmental changes, deforestation, intensive farming, and climate change increase the likelihood of cross-species transmission and disease spill over. One Health strategies aim to bring together professionals from human health, veterinary medicine, environmental science, and public policy to address these complex challenges. Surveillance of animal reservoirs, regulation of wildlife trade, and environmental risk assessment are central components. Cross-sector collaboration enhances early detection, improves outbreak preparedness, and supports global pandemic prevention. Education, funding, and political commitment are essential to operationalize One Health at national and international levels. By promoting interdisciplinary cooperation, One Health offers a sustainable framework to reduce infectious disease risks and strengthen global health security.

14. Vaccine Research and Development

Vaccines are among the most powerful tools in preventing infectious diseases and have saved millions of lives globally. Vaccine research and development (R&D) involves complex processes including pathogen identification, antigen discovery, preclinical testing, clinical trials, regulatory approval, and manufacturing. Traditional vaccines use inactivated or live-attenuated organisms, while newer platforms include mRNA, viral vectors, and protein subunits. The success of mRNA vaccines during the COVID-19 pandemic has accelerated interest in adaptable, rapid-response vaccine platforms. Challenges in vaccine development include pathogen variability, immune evasion, storage requirements, and ensuring safety and efficacy across diverse populations. Equitable access to vaccines remains a global concern, especially in low-resource settings. Continued investment in basic immunology, biotechnology, and public-private partnerships is essential. Future innovations may include universal vaccines, thermostable formulations, and personalized immunization strategies. Strong regulatory frameworks and global coordination are vital to ensure safe, effective, and timely vaccine delivery.

15. Climate Change, Urbanization, and Infectious Disease Spread

Climate change and rapid urbanization are increasingly influencing the emergence and spread of infectious diseases. Rising temperatures, changing rainfall patterns, and extreme weather events alter the habitats of vectors like mosquitoes and ticks, expanding the range of diseases such as malaria, dengue, chikungunya, and Lyme disease. Floods and droughts can compromise water quality, sanitation, and food supply, increasing risks of waterborne and foodborne illnesses. Urbanization, especially in low-income regions, often results in overcrowded living conditions with limited access to healthcare and clean resources, creating hotspots for disease transmission. Deforestation and human encroachment into wildlife habitats also increase the risk of zoonotic spill overs. Mitigating these risks requires interdisciplinary action across public health, urban planning, environmental protection, and policy development. Strengthening infrastructure, improving surveillance, and promoting climate-resilient health systems are key strategies. Understanding and addressing the links between environmental change and disease is crucial for future health security.

Market Analysis

The global infectious diseases market remains a critical area of medical and scientific focus due to the continuous emergence of new pathogens and the resurgence of previously controlled infections. With increasing global mobility, antimicrobial resistance (AMR), climate change, and urbanization, the risk and impact of infectious disease outbreaks have grown substantially.

Market Size & Growth

According to recent industry reports, the global infectious disease diagnostics market is projected to surpass USD 49 billion by 2026, growing at a CAGR of 6.5%. The broader infectious diseases therapeutics market, including antivirals, antibiotics, antifungals, and vaccines, is expected to reach USD 125+ billion, driven by growing investments in R&D, pandemic preparedness, and vaccine development.

Key Growth Drivers

Post-COVID-19 Global Health Strategy: Heightened focus on pandemic preparedness, rapid diagnostics, and vaccine infrastructure.
Technological Innovation: Growth in AI-powered diagnostics, point-of-care testing, molecular assays, and bioinformatics.
Public-Private Partnerships: Increased funding from governments and global health agencies for AMR surveillance and vaccine R&D.
Emerging Threats: Rise in zoonotic diseases, climate-driven outbreaks, and multi-drug-resistant organisms (MDROs).
Health Equity Initiatives: Expanding access to vaccines and treatments in low- and middle-income countries.

Conference Relevance

The 18th Euro-Global Conference on Infectious Diseases offers a vital opportunity to align academic research and clinical innovation with market demands. It provides a platform to:

Showcase new research and product innovations.
Explore investment and partnership opportunities.
Understand regulatory pathways and global policy trends.
Strengthen cross-sector collaborations to tackle global health threats.

Target Audience

Pharmaceutical & biotech companies
Medical device and diagnostics firms
Academic and clinical researchers
Public health organizations and policymakers
Investors and funding agencies

Conclusion:
The infectious diseases market continues to be a dynamic and essential field for scientific, clinical, and commercial innovation. The 18th Euro-Global Conference in London is strategically positioned to serve as a catalyst for knowledge exchange, collaboration, and market advancement in 2026 and beyond.

To Collaborate Scientific Professionals around the World

Conference Date April 16-17, 2026

For Sponsors & Exhibitors

sponsor@conferenceseries.com

Speaker Opportunity

Poster Opportunity E-Poster Opportunity

Useful Links

Past Conference Report

Euro Infectious Diseases 2025 Conference

Supported By

All accepted abstracts will be published in respective Conference Series International Journals.

Abstracts will be provided with Digital Object Identifier by

Infectious Diseases

April 16-17, 2026 London, UK

Conference Series Conferences gaining more Readers and Visitors